全文获取类型
收费全文 | 286篇 |
免费 | 17篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 6篇 |
基础医学 | 9篇 |
临床医学 | 8篇 |
内科学 | 26篇 |
皮肤病学 | 2篇 |
神经病学 | 17篇 |
外科学 | 10篇 |
综合类 | 22篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 100篇 |
中国医学 | 10篇 |
肿瘤学 | 97篇 |
出版年
2022年 | 1篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 3篇 |
2016年 | 3篇 |
2015年 | 5篇 |
2014年 | 7篇 |
2013年 | 21篇 |
2012年 | 3篇 |
2011年 | 8篇 |
2010年 | 10篇 |
2009年 | 7篇 |
2008年 | 10篇 |
2007年 | 18篇 |
2006年 | 17篇 |
2005年 | 17篇 |
2004年 | 11篇 |
2003年 | 7篇 |
2002年 | 13篇 |
2001年 | 16篇 |
2000年 | 10篇 |
1999年 | 16篇 |
1998年 | 4篇 |
1997年 | 14篇 |
1996年 | 9篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1990年 | 8篇 |
1989年 | 2篇 |
1988年 | 5篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 23篇 |
排序方式: 共有310条查询结果,搜索用时 696 毫秒
1.
Summary Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer. The dose of dipyridamole was fixed at 175 mg/m2 by mouth every 6 h (700 mg/m2/day), based upon a previous phase I trial of oral dipyridamole with 5-FU and leukovorin. Dipyridamole therapy began 24 h prior to the first dose of chemotherapy and continued until 24 h after the last dose of chemotherapy for each course of treatment. At the initial dose level, leukovorin 200 mg/m2 was given intravenously immediately prior to 5-FU 375 mg/ m2 intravenously on days 1–5. Mitoxantrone 6 mg/m2 was given as a single dose on day 3. Unacceptable toxicity was observed at this dose level, leading to successive dose decrements rather than dose increments. The maximum tolerated dose was leukovorin 200 mg/m2 days 1–2, 5-FU 375 mg/m2 days 1–2, mitoxantrone 6 mg/m2 on day 2, and dipyridamole 175 mg/m2 every 6 h on days 0–3. Two responses were produced in 15 patients. This regimen is not recommended for further investigation in the treatment of breast cancer. 相似文献
2.
Agustin Avils Bibiana Soto Renaldo Guzmn Edna L. García M. Jesús Nambo Jos C. Díaz-Maqueo 《Pediatric blood & cancer》1995,24(3):171-175
From January 1986 to December 1989, 157 previously untreated patients, with Hodgkin's disease stage I or II without bulky disease, were enrolled in a clinical comparative study. The objectives of the study were to compare the efficacy and safety of using epirubicine or mitoxantrone instead of adriamycin in the combination chemotherapy regimen ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine). The complete response rate was better in the patients treated with the ABVD or EBVD regimens compared to the MBVD arm. Also, differences in overall survival and relapse-free survival were better in the patients who received ABVD or EBVD compared to the MBVD regimen. Hematological, gastrointestinal and cardiac toxicity were similar in the three groups. Dose intensity, delays and complications were also similar in the three groups. The mitoxantrone-containing regimen was found to have less efficacy in comparison to the other regimens tested in the present study in patients with favorable stage I or II Hodgkin's disease. © 1995 Wi1ey-Liss Inc. 相似文献
3.
R. Metz M. Delgado R. Keiling P. Cappelaere J. P. Armand G. Prevot J. L. Misset J. Grimbert G. Mathe 《Investigational new drugs》1985,3(2):163-166
Summary In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose.After the EORTC Clinical Screening Group phase II trial we have conducted an expected difference method comparative phase II trial using the combination DOX, VCR, CPM, FU and the combination of MTX (10mg/m2), VCR, CPM and FU on a population of 50 breast carcinoma patients similar to those taking part in the first study.The reasons for similarity of action will be presented and discussed. 相似文献
4.
Summary Results of comparative studies on stimulation of the rates of cofactor consumption, superoxide generation and hydrogen peroxide production by mitoxantrone (Novantrone®; dihydroxyanthracenedione; MXN), ametantrone (AM), doxorubicin (DOX) and daunorubicin (DNR) in the presence of NADPH-cytochrome P-450 reductase, NADH dehydrogenase, or rabbit hepatic microsomes have been reported. MXN and AM were substantially less effective in stimulating the rate of cofactor oxidation, superoxide formation or hydrogen peroxide production relative to the anthracyclines. In the presence of P-450 reductase, the rate of NADPH oxidation or superoxide generation produced by 100 M MXN or AM was only 15% and 2% respectively of that produced by 100 M anthracycline.The effects of MXN and AM on lipid peroxidation in hepatic microsomes, cardiac sarcosomes and cardiac mitochondria were determined and compared with those produced by ADM. MXN and AM at 50 M inhibited the basal rate of NADPH-dependent rabbit liver microsomal lipid peroxidation by 50%; in contrast, DOX enhanced the rate of hepatic microsomal lipid peroxidation by 2-and 2.5-fold at 100 and 200 M, respectively. Rabbit cardiac sarcosomal NADPH-dependent lipid peroxidation was inhibited completely at 100 M anthracenedione. NADH-dependent lipid peroxidation in cardiac mitochondria was diminished by 50 M MXN and AM, whereas 50 M DOX produced a 2-fold stimulation in lipid peroxidation. The anthracenediones also effectively inhibited DOX-stimulated lipid peroxidation with 50% inhibition occurring at 4 M (MXN) and 6 M (AM). Moreover, both MXN and AM potently inhibited iron (100 M)-stimulated lipid peroxidation in rabbit hepatic microsomes with 80% inhibition produced by 15 M anthracenedione.These results are consistent with the diminished cardiotoxicity of mitoxantrone and ametantrone relative to DOX or DNR and may require a reassessment of the role of lipid peroxidation in the mechanism(s) of quinone antineoplastic agent-mediated cardiotoxicity. 相似文献
5.
Dominique Bron Dr Pierre Dodion Marcel Rozencweig Alain Delforge Marie-Anne Mattelaer Yvon Kenis Pierre Stryckmans 《Investigational new drugs》1986,4(1):11-16
The effect of 3 anthracene derivatives, mitoxantrone, ametantrone, bisantrene, on 4 normal human bone marrows, was studied using the myeloid stem cell assay developed by Pike and Robinson, in order to define to what extent this test could be used to predict the relative clinical hematologic toxicity of new anticancer agents. For the 3 drugs, an exponential relationship between colony survival and drug concentration was found, but was much steeper for mitoxantrone (slope = -195.2 ± 8.8/g/ml) than for ametantrone (slope = 5.1 ± 1.0/g/ml, p0.001) and bisantrene (slope = 7.1 ± 0.3/g/ml, p0.001). The difference of slope between ametantrone and bisantrene was of borderline significance (p0.05). The ratios of concentrations inducing a 50% growth inhibition for mitoxantrone versus bisantrene and for ametantrone versus bisantrene were close to the corresponding ratios of concentrations inducing a 90% growth inhibition. The relative in vitro toxicities reproduce very well the relative myelosuppression observed in clinical trials with mitoxantrone versus bisantrene but the results were less satisfactory for the comparison of these 2 agents with ametantrone. In addition, our data suggest that, for these 3 compounds, intrinsic myeloid progenitor sensitivity is a major determinant of leukopenia. 相似文献
6.
目的:评价含米托蒽醌的联合化疗方案(HAM) 治疗老年急性髓系白血病(AML) 。方法:比较应用HAM 方案治疗老年AML36 例与标准DA 方案治疗老年AML23 例及HAM 方案治疗中青年AML53 例的治疗效果。结果:(1)HAM 方案治疗老年AML 与DA 方案比较两者CR 率无显著性差异,但HAM 方案可使患者缓解迅速且中位缓解期较DA 方案长;(2)HAM 方案治疗老年AML 较年轻患者CR 率低且缓解期短;(3) 米托蒽醌主要毒性作用为骨髓抑制HAM 方案诱导相关死亡率并无增高。结论:HAM 方案可作为老年AML 的一种较好的治疗方案。 相似文献
7.
Christian M. Kurbacher Ian A. Cree Ursula Brenne Howard W. Bruckner Jutta A. Kurbacher Peter Mallmann Peter E. Andreotti Dieter Krebs 《Breast cancer research and treatment》1996,41(2):161-170
Summary Apart from clinical trials, mitoxantrone (MX) is rarely used in breast cancer (BC) due to the anticipated anthracycline cross-resistance. We have examined this drug versus doxorubicin (DOX) using data obtained fromin vitro microplate ATP tumor chemosensitivity assays (ATP-TCA) of BC cells which were derived from 55 chemotherapy-naive patients at time of primary surgery. Both drugs were tested at 6 different concentrations ranging from 6.25% to 200% peak plasma concentrationin vivo (PPC). Differences between DOX and MX observed for mean IC50, IC90, and a sensitivity index (SI) were not statistically significant.In vitro response rates were 44% for DOX and 52% for MX. 34 of 52 eligible assays (65%) showed comparable activity of both drugs whereas a lack of cross-resistance was observed in the remaining 18 (35%) tumors as indicated by differences for SI. Cumulative concentration-response plots of tumors respondingin vitro with a 50 percent or 90 percent tumor cell inhibition showed a strong dose-dependence for both DOX and MX at concentrations which normally can be achieved within clinical tumors (i.e. 6.25%-50% PPC). At higher concentrations, however, cytotoxicity of DOX and MX could not be improved by furtherin vitro dose escalation. Moreover, a substantial proportion of BC specimens (DOX: 48.1%; MX: 40.4%) did not experience a 90 tumor cell inhibition at 200% PPC. In conclusion,in vitro results obtained by ATP-TCA indicate that there is no cross-resistance between MX and DOX in a substantial proportion of BC patients. This may be clinically useful and suggests that combinations including MX should be tested in patients clinically resistant to DOX containing regimens. Since both drugs produced sigmoidal concentration-response curves, dose escalation beyond a certain point may not produce increased sensitivity. 相似文献
8.
目的制备N-(2-羟丙基)甲基丙烯酰胺(HPMA)聚合物-米托蒽醌(DHAQ)接合物以提高DHAQ在实体瘤中的分布。方法采用DHAQ与四肽间隔基连接,再与HPMA进行自由基沉淀聚合反应的方法,合成目标接合物;考察了接合物在不同介质中的稳定性及荷瘤小鼠体内的分布情况。结果合成的接合物经UV,HPLC和FPLC鉴定为目标化合物。其总DHAQ含量为132.4 mg·g-1接合物,游离DHAQ含量为3.5 mg·mg-1接合物。摩尔质量19 000 g·mol-1,分子量分布1.4。在不同pH磷酸盐缓冲液及血浆中较稳定,在肿瘤中的释药明显加快。与原药相比,接合物在荷瘤小鼠体内的分布明显不同。肿瘤中AUC为游离药物3倍;血液循环时间延长;在心脏中的分布明显减少。表明接合物具有一定的肿瘤趋向性,并能降低原药对心脏的毒性。结论将具有仲氨基的DHAQ连接于HPMA聚合物,能提高DHAQ在肿瘤中的分布,为实体瘤靶向高分子给药系统的研究提供新的思路。 相似文献
9.
MA方案治疗成人急性非淋巴细胞白血病的疗效分析 总被引:2,自引:0,他引:2
[目的]评价米托蒽醌、阿糖胞苷(MA)方案作诱导治疗成人急性非淋巴细胞白血病(ANLL)初治患者的疗效。[方法]对诊断明确者分为M1、M2型及M4、M5型,各型内部随机分为MA组和柔红霉素、阿糖胞苷(DA)组,1、2个疗程后,分别评价疗效。[结果]M1、M2型中,MA、DA组1个疗程后CR分别为70.0%、63.6%,2个疗程总CR分别为75.0%、68.2%,总有效率分别为85.0%、81.8%,两组间均无显著性差异。M4、M5型中,MA、DA组1个疗程CR分别为68.8%、33.3%,两者有显著差异,而2个疗程总CR分别为68.8%、46。7%,总有效率分别为81.3%、60.0%,两组问无显著性差异。MA组骨髓抑制作用强于传统DA组。[结论]MA方案可作为成人ANLL(M4、M5)首选诱导治疗方案。 相似文献
10.
联合应用化疗药物对三氧化二砷耐药白血病细胞的毒性实验研究 总被引:1,自引:0,他引:1
目的:探讨化疗药物联合应用对三氧化二砷(As2O3)耐药白血病细胞(K562/AS2)的毒性作用。方法:细胞毒实验采用MTT法,二药合用时细胞毒性作用采用ChouTalalay联合指数法分析,细胞表面P糖蛋白(Pgp)和细胞内柔红霉素(DNR)浓度测定采用流式细胞术测定。结果:K562/AS2细胞对三氧化二砷、柔红霉素、鬼臼乙叉苷(VP16)、三尖杉酯碱(H)、米托蒽醌(NVT)和阿糖胞苷(AraC)的耐药倍数分别为7.4、2.9、3.8、3.6、2.8和1.1。K562细胞和K562/AS2细胞的细胞表面Pgp或细胞内任意荧光强度无显著的统计学意义(P>0.05)。As2O3与DNR、VP16、H或NVT联合应用时,对K562、K562/AS2和Pgp表达的白血病细胞(K562/A02)细胞的联合指数均大于1。异搏定与DNR联合应用时,对K562和K562/AS2细胞的联合指数均大于1,但是对K562/A02细胞的联合指数均小于1。结论:K562/AS2细胞对As2O3、DNR、VP16和NVT耐药,其机制与Pgp表达无关。异搏定联合应用DNR可以逆转K562/A02对DNR的耐药性,不能逆转DNR对As2O3耐药细胞的耐药性。As2O3与DN、VP16、H和NVT联合应用时,对K562、K562/AS2和K562/A02细胞的毒性均为拮抗作用。 相似文献